These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 22098560)

  • 1. Reprogramming urokinase into an antibody-recruiting anticancer agent.
    Jakobsche CE; McEnaney PJ; Zhang AX; Spiegel DA
    ACS Chem Biol; 2012 Feb; 7(2):316-21. PubMed ID: 22098560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
    Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
    J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor.
    Rullo AF; Fitzgerald KJ; Muthusamy V; Liu M; Yuan C; Huang M; Kim M; Cho AE; Spiegel DA
    Angew Chem Int Ed Engl; 2016 Mar; 55(11):3642-6. PubMed ID: 26879524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase plasminogen activator system as a potential target for cancer therapy.
    Mekkawy AH; Morris DL; Pourgholami MH
    Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
    Abi-Habib RJ; Singh R; Liu S; Bugge TH; Leppla SH; Frankel AE
    Mol Cancer Ther; 2006 Oct; 5(10):2556-62. PubMed ID: 17041100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
    Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
    J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy.
    Lund IK; Illemann M; Thurison T; Christensen IJ; Høyer-Hansen G
    Curr Drug Targets; 2011 Nov; 12(12):1744-60. PubMed ID: 21707477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase receptor variants in tissue and body fluids.
    Høyer-Hansen G; Lund IK
    Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tristetraprolin inhibits the growth of human glioma cells through downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor mRNAs.
    Ryu J; Yoon NA; Lee YK; Jeong JY; Kang S; Seong H; Choi J; Park N; Kim N; Cho WJ; Paek SH; Cho GJ; Choi WS; Park JY; Park JW; Kang SS
    Mol Cells; 2015; 38(2):156-62. PubMed ID: 25556371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.
    Chavakis T; Kanse SM; Yutzy B; Lijnen HR; Preissner KT
    Blood; 1998 Apr; 91(7):2305-12. PubMed ID: 9516128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
    Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
    Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
    Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
    Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics.
    Schmiedeberg N; Schmitt M; Rölz C; Truffault V; Sukopp M; Bürgle M; Wilhelm OG; Schmalix W; Magdolen V; Kessler H
    J Med Chem; 2002 Nov; 45(23):4984-94. PubMed ID: 12408709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of MDA-MB-231 cell line by peptides designed based on uPA.
    Tarighi P; Khorramizadeh M; Madadkar-Sobhani A; Ostad S; Ghahremani M
    Acta Med Iran; 2015 Jul; 53(7):403-7. PubMed ID: 26520626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitors regulate cell adhesion through a uPAR-dependent mechanism.
    Czekay RP; Loskutoff DJ
    J Cell Physiol; 2009 Sep; 220(3):655-63. PubMed ID: 19472211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
    Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
    RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.